COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00323817
Recruitment Status : Completed
First Posted : May 10, 2006
Last Update Posted : May 28, 2015
Information provided by:
Zeria Pharmaceutical

Brief Summary:
To evaluate the efficacy and safety of Z-338 in subjects with Functional Dyspepsia

Condition or disease Intervention/treatment Phase
Functional Dyspepsia Drug: Z-338 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 282 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Study Start Date : April 2006
Actual Primary Completion Date : April 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion

Primary Outcome Measures :
  1. Global subject Outcome Assessment [ Time Frame: 12 month ]

Secondary Outcome Measures :
  1. Individual symptom [ Time Frame: 12 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects presenting diagnosis of FD as defined by the Rome II
  • Subjects presenting postprandial fullness and/or Early satiety should be the most bothersome symptom

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00323817

Layout table for location information
Leuven University
Leuven, Belgium
Sponsors and Collaborators
Zeria Pharmaceutical
Layout table for investigator information
Principal Investigator: Jan Tack, PhD, MD Leuven University
Layout table for additonal information Identifier: NCT00323817    
Other Study ID Numbers: 99010206E
First Posted: May 10, 2006    Key Record Dates
Last Update Posted: May 28, 2015
Last Verified: May 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Z 338
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Gastrointestinal Agents